KSPM
Search
- Page Path
- HOME > Search
English Abstract
- Use of Economic Evaluation in the Listing and Pricing of Pharmaceuticals.
- Tae Jin Lee
- J Prev Med Public Health. 2008;41(2):69-73.
- DOI: https://doi.org/10.3961/jpmph.2008.41.2.69
- 4,455 View
- 56 Download
- 5 Crossref
-
Abstract
PDF - To curb a rapid increase in expenditures for pharmaceuticals, the Korean government introduced a positive list system and a negotiation process for drug prices at the end of 2006. Economic evaluation of pharmaceuticals has begun to have a pivotal role in the listing and pricing of drugs for the Korean National Health Insurance. There are some points to discuss regarding the use of economic evaluation in the listing and pricing in the context of the Korean system. First, the listing and pricing processes have been fragmented, evoking complaints from pharmaceutical companies and delaying the access of new drugs to patients. Second, there is a concern that the positive list system may limit the range and availability of drugs for patients to choose for treatment. Third, the time schedule for de-listing of existing drugs may not be realistic. Fourth, it is not always easy to provide reliable evidence of cost-effectiveness due to a lack of materials. Fifth, there is no consensus on the range of the ICER (incremental cost-effectiveness ratio) acceptable to the Korean society. In conclusion, in the near future, it will be necessary to evaluate the achievements that the economic evaluation has provided to the Korean society.
-
Summary
Citations
Citations to this article as recorded by
- Cost-effectiveness of rhythm control strategy: Ablation versus antiarrhythmic drugs for treating atrial fibrillation in Korea based on real-world data
Woojin Kim, Min Kim, Yun Tae Kim, Woongbi Park, Jin-bae Kim, Changsoo Kim, Boyoung Joung
Frontiers in Cardiovascular Medicine.2023;[Epub] CrossRef - Policy Suggestions to Improve Patient Access to New Drugs in Korea
Yoona Choi, Howard Lee
Korean Journal of Clinical Pharmacy.2021; 31(1): 1. CrossRef - Consistency of new drug pricing in Korea: Bridging variations among personnel in price negotiations
Hye-Young Kwon, Jinhyun Kim
Health Policy.2020; 124(9): 965. CrossRef - How Much Amount of Socioeconomic Loss Is Caused by Digestive Diseases?
Kyung Sik Park
The Korean Journal of Gastroenterology.2011; 58(6): 297. CrossRef - Health Care Costs of Digestive Diseases in Korea
Hye-kyung Jung, BoHyoung Jang, Youn Hee Kim, JooYeon Park, Sun Young Park, Mi-Hee Nam, Myung-Gyu Choi
The Korean Journal of Gastroenterology.2011; 58(6): 323. CrossRef
First
Prev
